Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ninerafaxstat
- Development stage
- Phase 2
- Lead developer
- Imbria Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ninerafaxstat (IMB-1018972) is a first-in-class, investigational small molecule cardiac mitotrope being developed by Imbria Pharmaceuticals. It acts as a partial fatty acid oxidation (pFOX) inhibitor, designed to shift the heart's metabolic preference from fatty acids toward glucose. This metabolic shift enhances mitochondrial energy efficiency, potentially improving cardiac function without affecting heart rate, blood pressure, or rhythm. It is currently being evaluated in Phase 2 clinical trials for cardiovascular conditions including stable angina due to obstructive coronary artery disease, non-obstructive hypertrophic cardiomyopathy (nHCM), and heart failure with preserved ejection fraction (HFpEF).
- Brand names
- IMB-101IMB101IMB 101
- Other names
- ninerafaxstat
02
Targets
HADHB (Long-chain 3-ketoacyl-CoA thiolase)
Beyond the preview
Go deeper on ninerafaxstat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ninerafaxstat.